Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase IIb/III randomized double-blind placebo-controlled study of atacicept in IgA nephropathy
CTR20242150Phase 3Active
- Sponsor
- Vera Therapeutics
- Start
- Jun 2024
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of atacicept in IgA nephropathy (IgAN), sponsored by Vera Therapeutics. Started Jun 2024; status: active.
02
Drugs
atacicept
03
Conditions
IgA nephropathy (IgAN)
Beyond the preview
Go deeper on CTR20242150.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20242150.